Literature DB >> 12530097

The prognostic significance of epithelial-mesenchymal transition in breast cancer.

Ilka B Fuchs1, Werner Lichtenegger, Helmut Buehler, Wolfgang Henrich, Harald Stein, Anke Kleine-Tebbe, Gerhard Schaller.   

Abstract

BACKGROUND: This study investigates the influence of epithelial-mesenchymal transition on prognosis in breast cancer.
MATERIALS AND METHODS: Eighty breast carcinomas as well as 6 breast cancer cell lines were analysed immunohistochemically for the expression of epithelial keratins (K) K8, K19 and mesenchymal vimentin. Protein expression was correlated with histopathological factors and clinical follow-up.
RESULTS: Suppression of K8 and K19 occurred in the majority of the tumours (72.5% and 65%), while aberrant expression of vimentin was found in 21.2% of the tumours. Suppression of K8 as well as expression of vimentin was significantly correlated with short survival (p < 0.004 and p < 0.006). Moreover HER2 overexpression significantly correlated with K19 (p < 0.0004) and vimentin (p < 0.0005). In cell lines with increasing invasive potential, epithelial keratins were lost in favour of mesenchymal vimentin.
CONCLUSION: The transition from epithelial keratin to mesenchymal vimentin expression marks an important step in the malignant progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530097

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  25 in total

1.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

2.  Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta.

Authors:  Bradley Yates; Craig Zetterberg; Vaishali Rajeev; Michael Reiss; Susan R Rittling
Journal:  Exp Cell Res       Date:  2007-08-01       Impact factor: 3.905

3.  KRAS and YAP1 converge to regulate EMT and tumor survival.

Authors:  Diane D Shao; Wen Xue; Elsa B Krall; Arjun Bhutkar; Federica Piccioni; Xiaoxing Wang; Anna C Schinzel; Sabina Sood; Joseph Rosenbluh; Jong W Kim; Yaara Zwang; Thomas M Roberts; David E Root; Tyler Jacks; William C Hahn
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

4.  Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.

Authors:  Nancy Dumont; Matthew B Wilson; Yongping G Crawford; Paul A Reynolds; Mahvash Sigaroudinia; Thea D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

5.  ASK-ing EMT not to spread cancer.

Authors:  Natasha Kyprianou
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-09       Impact factor: 11.205

Review 6.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

7.  Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1.

Authors:  M G di Bari; E Ginsburg; J Plant; L Strizzi; D S Salomon; B K Vonderhaar
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

8.  Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.

Authors:  Meng-Lei Zhu; Natasha Kyprianou
Journal:  FASEB J       Date:  2009-11-09       Impact factor: 5.191

9.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

10.  Molecular characterisation of breast cancer patients at high and low recurrence risk.

Authors:  Serena Bonin; Davide Brunetti; Elena Benedetti; Isabella Dotti; Nader Gorji; Giorgio Stanta
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.